Sysqo · Extending Human Lifespan

The mission.

This is the most ambitious thing Sysqo works on, and we treat it with the weight it deserves. We direct our scientific work toward extending healthy human lifespan: the biology of ageing, age-related disease, and the long goal of dramatically extending how long, and how well, people live.

Ageing as a modifiable process.

The frame

For most of medical history, ageing has been treated as a fixed backdrop rather than something we can change. Yet it remains the single largest risk factor behind the chronic diseases that cause most deaths worldwide. The central question now is whether ageing can be measured accurately, separated from simple chronological time, and slowed or reversed without causing more harm than good. This is difficult because ageing does not happen uniformly. It moves at different speeds across organs, tissues, and even individual cells, and testing whether something works in humans can take decades.

The evidence

Recent research suggests real progress. Two decades of rigorous mouse studies have established rapamycin as the most reliable drug for extending lifespan, with effective compounds tending to target metabolism, stress, and inflammation. In humans, early trials of senolytics, drugs that clear worn-out “senescent” cells, have shown these cells can be removed safely. Partial cellular reprogramming, which resets the markers of age in living cells, has more than doubled the remaining lifespan of aged mice without causing tumours. Meanwhile, AI is being used to measure biological age from medical images and to identify new drug targets that address ageing and disease at once.

The work

These findings also reveal where the field must go next, and these are the questions Sysqo is built to pursue. The most urgent is validation: too many AI-led studies rely on small or biased datasets and skip confirmation in living systems. Progress will require careful replication, measurement at the level of specific organs and cells, and study designs that test how interventions work in combination rather than alone, since lasting results are unlikely to come from any single treatment. Sysqo sees the disciplined work of turning these discoveries into proven, measurable outcomes as the core challenge of applied longevity research, and as the work it exists to do.

What we build.

01Molecular property predictionTriaging candidate molecules in silico before they reach the wet lab, narrowing vast libraries to the few worth the bench time.

02Protein structure & interaction modellingPredicting how proteins fold and bind, to understand the machinery of ageing and the targets that might intervene in it.

03Generative chemistryProposing novel candidate structures against a target profile, exploring chemical space far faster than enumeration allows.

04Experimental design optimisationSharpening the design, make, test, analyse cycle so each round of experiments learns the most from the fewest runs.

05Validation in living systemsDesigning the studies that confirm an AI-led finding outside the model: replication, measurement at organ and cell level, and combinations of interventions where single ones rarely hold.

Reading the whole of the literature, grounded and cited.

No researcher can read everything. We build AI systems that read and synthesise the global research literature, surfacing what is already known so scientists can spend their attention on what is still open.

Every synthesis is grounded in its sources and cited. The systems are engineered toward zero plagiarism by design, through citation and grounding, so the output can be traced, checked, and trusted as a starting point for real work.

What changes.

years → months

Compressing early discovery timelines

orders of mag.

Candidate libraries narrowed before the bench

Working alongside a research group on the biology of ageing, using literature synthesis and in silico screening to focus a long programme of experimental work on its most promising directions.